FDA approves Orca Bio T-cell therapy to reduce graft-versus-host disease risk

The US Food and Drug Administration has approved a T-cell therapy developed by Orca Bio for use in patients with blood cancers who are undergoing haematopoietic stem cell transplants, according to reporting by STAT News. The therapy is intended to reduce the risk of graft-versus-host disease, a serious and potentially life-threatening immune complication in which transplanted donor cells attack the recipient's tissues.

Graft-versus-host disease is a major cause of morbidity and mortality after allogeneic stem cell transplantation, and options to mitigate it while preserving the graft-versus-tumour effect remain an active area of research and clinical development. Orca Bio's approach involves precision engineering of the donor cell product to alter the composition of immune cell subsets transferred to the recipient.

Full details of the product's mechanism, trial data, and approved indication are behind a STAT+ paywall. The approval is relevant to oncologists managing patients with haematological malignancies, to researchers in transplant immunology, and to genetic counsellors working with hereditary blood cancer families for whom transplant may be a clinical consideration.